Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17150911 | 1.00 | JAK3 (0.41) | JAK3ALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL18455437 | 0.98 | JAK3 (0.41) | JAK3ALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL24244462 | 0.94 | MAPT (0.41) | JAK3ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL19190151 | 0.84 | RAB9A (0.41) | JAK3ALDH1A1SMN1; SMN2MEN1NPC1 | |
| SCHEMBL18285080 | 0.84 | JAK3 (0.38) | JAK3POLBEGFR | |
| SCHEMBL18285079 | 0.84 | JAK3 (0.38) | JAK3POLBEGFR | |
| SCHEMBL16078787 | 0.84 | POLB (0.45) | ALDH1A1RAB9AL3MBTL1POLB | |
| SCHEMBL24113593 | 0.82 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2MEN1NPC1RAB9A | |
| SCHEMBL19497181 | 0.82 | BCHE (0.38) | ALDH1A1SMN1; SMN2MEN1NPC1RAB9A | |
| SCHEMBL12841131 | 0.82 | JAK3 (0.42) | JAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560959-B1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| EP-4245376-A2 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | Novartis AG (CH) | 2023-09-20 | — | — | EP | disclosed |
| EP-3206711-B1 | ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF | NOVARTIS AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| US-20230146638-A1 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | G1 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11344620-B2 | Combination therapies | NOVARTIS AG (CH) | 2022-05-31 | — | — | US | disclosed |
| EP-3950686-A1 | N-HETEROAROMATIC AMIDE DERIVATIVES FOR TREATMENT OF CANCER | Shenzhen Forward Pharmaceuticals Co., Ltd. (CN) | 2022-02-09 | — | — | EP | disclosed |
| EP-3925622-A1 | COMBINATION THERAPIES | Novartis AG (CH) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021224867-A1 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND NAZARTINIB | NOVARTIS AG (CH) | 2021-11-11 | — | — | WO | disclosed |
| EP-3878465-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | Novartis AG (CH) | 2021-09-15 | — | — | EP | disclosed |
| EP-3317301-B1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3 | NOVARTIS AG (CH) | 2021-04-07 | — | — | EP | disclosed |
| EP-3660050-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | Novartis AG (CH) | 2020-06-03 | — | — | EP | disclosed |
| EP-3116909-B1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | NOVARTIS AG (CH) | 2019-11-13 | — | — | EP | disclosed |
| EP-3560959-A1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | Novartis AG (CH) | 2019-10-30 | — | — | EP | disclosed |
| EP-3514179-A1 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3099717-B1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-9993551-B2 | Combination therapies of EGFR inhibitors | NOVARTIS AG (CH) | 2018-06-12 | — | — | US | disclosed |
| US-20170304443-A1 | COMBINATION THERAPIES OF EGFR INHIBITORS | NOVARTIS PHARMACEUTICALS CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170296659-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2017-10-19 | — | — | US | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| EP-2773635-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170296659-A1 | COMBINATION THERAPIES | MET, BRAF, ERBB2 | JAK3 42/4885ALDH1A1 1188/4885SMN1; SMN2 3949/4885 |
| US-11344620-B2 | Combination therapies | MET, BRAF, ERBB2 | JAK3 42/4885ALDH1A1 1188/4885SMN1; SMN2 3949/4885 |
| US-20170304443-A1 | COMBINATION THERAPIES OF EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | JAK3 51/4885ALDH1A1 2428/4885SMN1; SMN2 4486/4885 |
| US-20230146638-A1 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | EGFR, CDK4, CDK6 | JAK3 149/4885ALDH1A1 2122/4885SMN1; SMN2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.